Effect of anti-vascular endothelial growth factor in treating diabetic macular edema
-
摘要: 目的 观察抗血管内皮生长因子(VEGF)治疗糖尿病性黄斑水肿(DME)的效果和对血清一氧化氮合酶(NOS)、VEGF、白细胞介素-6(IL-6)水平及鼻侧睫状后动脉血流动力学参数的影响。 方法 选取98例DME患者(122眼)作为研究对象,均给予抗VEGF治疗,将治疗敏感者56例(72眼)纳入敏感组,将治疗不敏感者42例(50眼)纳入对照组,比较2组治疗前后黄斑中心凹视网膜厚度、鼻侧睫状后动脉血流动力学参数和血清NOS、VEGF和IL-6水平等。 结果 敏感组视网膜外丛状层连续性中断率为9.72%, 低于对照组的72.00%, 差异有统计学意义(P<0.05); 治疗后,敏感组黄斑中心凹视网膜厚度为(301.12±67.28)μm, 小于对照组的(410.11±52.21)μm, 差异有统计学意义(P<0.05); 治疗后,敏感组收缩期峰值血流速度(PSV)、舒张末期血流速度(EDV)均高于对照组,差异有统计学意义(P<0.05); 治疗后,敏感组NOS水平高于对照组, VEGF、IL-6水平低于对照组,差异有统计学意义(P<0.05)。 结论 抗VEGF治疗DME有一定效果,治疗敏感者的黄斑中心凹视网膜厚度、鼻侧睫状后动脉血流动力学参数和血清NOS、VEGF及IL-6水平明显优于治疗不敏感者。Abstract: Objective To observe the effect of anti-vascular endothelial growth factor(VEGF)in treating diabetic macular edema(DME)and its effects on serum nitric oxide synthase(NOS), VEGF, interleukin-6(IL-6)and hemodynamic parameters of nasal posterior ciliary artery. Methods A total of 98 patients(122 eyes)with DME treated with anti-VEGF were selected as research objects, and 56 patients(72 eyes)who were sensitive to treatment were included in the sensitive group, and 42 patients(50 eyes)who were insensitive to treatment were included in the control group. The macular fovea retinal thickness and hemodynamic parameters of nasal posterior ciliary artery, levels of NOS, VEGF and IL-6 were measured before and after treatment. Results The continuous interruption rate of extraretinal plexiform layer in the treatment sensitive group was 9.72%, which was significantly lower than 72.00% in the treatment insensitive group(P<0.05). The retinal thickness of macular fovea in the sensitive group after treatment was(301.12±67.28)μm, which was significantly lower than(410.11±52.21)μm in the control group(P<0.05). The peak systolic blood flow velocity(PSV)and end diastolic blood flow velocity(EDV)in the treatment sensitive group after treatment were significantly higher than those in the treatment insensitive group(P<0.05). After treatment, the NOS level in the sensitive group was significantly higher than that in the control group(P<0.05), while the levels of VEGF and IL-6 were significantly lower than those in the control group(P<0.05). Conclusion Anti-VEGF therapy has a certain effect in treating DME. Retinal thickness of macular fovea, hemodynamic parameters of nasal posterior ciliary artery, levels of serum NOS, VEGF and IL-6 are significantly better in sensitive patients than those without sensitivity.
-
-
WYKOFF C C, MARCUS D M, MIDENA E, et al. Intravitreal aflibercept injection in eyes with substantial vision loss after laser photocoagulation for diabetic macular edema[J]. JAMA Ophthalmol, 2017, 135(2): 107-110.
ACAN D, CALAN M, ER D, et al. The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey[J]. BMC Ophthalmol, 2018, 18(1): 91-93.
CHATZIRALLI I, CHATZIPANTELIS A, DIMITRIOU E, et al. Refractive changes after anti-VEGF injections for diabetic macular edema[J]. Acta Ophthalmol, 2017, 95(259): 1-5.
HOLEKAMP N M, CAMPBELL J, ALMONY A, et al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice[J]. Am J Ophthalmol, 2018, 191(1): 83-91.
PAYNE J F, WYKOFF C C, CLARK W L, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema[J]. Ophthalmology, 2017, 124(1): 74-81.
徐芳, 赵淼焱, 刘菊. 糖尿病视网膜病变患者脉络膜厚度和血流动力学参数的变化及其影响因素[J]. 国际眼科杂志, 2016, 16(6): 1052-1055. 阳艳, 王燕, 俞晓艺, 等. 滋肾健脾化瘀片联合激光治疗对DME患者黄斑区视网膜厚度及血清NOS、VEGF、IL-6的影响[J]. 中国中医眼科杂志, 2018, 28(3): 28-31. 尚利晓, 杨洁琼, 付立红. 眼底激光联合抗VEGF药物治疗对糖尿病黄斑水肿患者血清NOS、VEGF和IL-6的影响[J]. 国际眼科杂志, 2018, 18(4): 634-637. 黄玥, 沈碧波, 赵东升. 糖尿病黄斑水肿对抗VEGF药物治疗的不同反应与糖尿病视网膜病变程度的相关性[J]. 国际眼科杂志, 2017, 17(2): 348-350. 王韫智, 郑志. 光相干断层扫描联合微视野检查在糖尿病黄斑水肿中的应用研究进展[J]. 中华眼底病杂志, 2018, 34(4): 404-407. 王建伟, 接传红, 陶永健, 等. 糖尿病黄斑水肿患眼黄斑区视功能与黄斑中心凹视网膜厚度的相关性分析[J]. 中华眼底病杂志, 2017, 33(3): 267-270. 颜浩, 古蓉, 王国华. 4种血管内皮功能指标评价糖尿病视网膜病变的价值研究[J]. 现代中西医结合杂志, 2018, 27(15): 1655-1658. 姬明利, 赵奎卿. 曲安奈德联合雷珠单抗治疗对糖尿病性黄斑水肿患者血清VEGF、IL-6、IL-8水平的影响[J]. 中国中医眼科杂志, 2017, 27(6): 380-383. 吴学蕊, 林贞丽, 窦晓燕, 等. 抗VEGF药物治疗糖尿病黄斑水肿临床研究进展[J]. 深圳中西医结合杂志, 2017, 27(7): 187-190. 杨秀芬, 尤冉, 赵露, 等. 全视网膜光凝治疗对糖尿病视网膜病变患者生活质量的影响[J]. 中华眼科杂志, 2018, 54(8): 611-616. 杨安怀, 胡焰山, 李拓. 抗VEGF药物治疗糖尿病性黄斑水肿的疗效与视网膜外丛状层连续性的相关性分析[J]. 临床眼科杂志, 2017, 25(5): 393-396. -
期刊类型引用(7)
1. 陈华茂，庄桂娟. 阿柏西普与雷珠单抗治疗糖尿病黄斑水肿的临床效果及安全性比较. 大医生. 2024(11): 92-95 . 
百度学术
2. 马楠，何敬，王淑珍. 抗血管内皮细胞因子与抗炎药物治疗不同类型视网膜静脉阻塞继发黄斑水肿的疗效对比. 临床合理用药. 2023(06): 145-148 . 百度学术
3. 田涛，姚晓喜，彭婧利，李植源，冯刚华，刘茹，周小平，杨源，邝国平. 不同抗VEGF药物治疗糖尿病性黄斑水肿的疗效及其与OCT分型的关系. 国际眼科杂志. 2023(06): 991-995 . 百度学术
4. 展复霞，刘志跃，赵雁玲. 探讨玻璃体腔注射抗VEGF药物联合激光治疗糖尿病性黄斑水肿的应用效果. 世界复合医学. 2023(07): 44-47 . 百度学术
5. 彭烨，胡龙. 复方樟柳碱结合阿柏西普对糖尿病性黄斑水肿患者视功能、CMT及眼压变化的影响. 生命科学仪器. 2023(05): 175-178 . 百度学术
6. 张海彬. 芪明颗粒与眼内抗血管内皮生长因子联合治疗糖尿病黄斑水肿临床效果研究. 糖尿病新世界. 2022(01): 13-17 . 百度学术
7. 巨朝娟，张骞颖，邢朋欣，石笑楠，张新. 抗血管内皮细胞生长因子治疗糖尿病性黄斑水肿的疗效及光学相干断层扫描血管造影结果分析. 中国现代医学杂志. 2022(10): 36-41 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 374
- HTML全文浏览量: 40
- PDF下载量: 9
- 被引次数: 8
下载:
苏公网安备 32100302010246号